The manufacturing process is housed at a facility in England through a partnership with Thermo Fisher Scientific Pharma Services, according to an Aug. 2 news release. Products made at the facility are expected to sell later in the year.
“This FDA approval underscores the quality assurance of our enhanced manufacturing process, which is essential as we scale the production of Exparel,” CEO and Chair Dave Stack said. “Launching this new manufacturing site marks an important milestone for Pacira that will allow us to double our capacity to meet the growing demand for Exparel, while simultaneously improving our gross margins and extending our market exclusivity into 2041.”
At the Becker’s 32nd Annual Meeting: The Business and Operations of ASCs, taking place October 29-31 in Chicago, ASC leaders, surgeons and healthcare executives will explore strategies to drive growth, enhance operational performance, navigate reimbursement challenges and prepare for the future of ambulatory surgery. Apply for complimentary registration now.
